CALR and synovial sarcoma: The distribution of SSc-specific auto-antibodies in our patients is as follows: NOR90 in 7/29 (24%) patients, Th/To in 7/29 (24%), Ku in 5/29 (17%), Ro52 in 5/29 (17%), CENP-B in 4/29 (14%), CENP-A in 3/29 (10%), RP155 in 3/29 (10%), RP11 in 2/29 (7%), PM/Scl 75 in 2/29 (7%), and finally Scl70 in 1/29 (3.5%), PM/Scl 100 in 1/29 (3.5%), and Fibrillarin in 1/29 (3.5%), while 4/29 (14%) patients had positive anti-Ro/SSA antibodies, still without fulfilling 2016 SS classification criteria.